Jump to content

Main Page: Difference between revisions

From Neoplasm
← Older editNewer edit →
VisualWikitext
No edit summary
Replaced content with "{{DISPLAYTITLE:}} NOTOC Neoplasm.org is an open-access knowledge base dedicated to the rapid dissemination of oncology clinical trial results and evidence-based treatment regimens. Modeled after the collaborative spirit of the medical community, our mission is to translate complex research into actionable clinical insights—free of charge and accessible to everyone, from oncologists and researchers to students and patients. {| class="wikitable neoplasm-table" |- |..."
Tag: Replaced
Line 1: Line 1:
{{DISPLAYTITLE:<span style="display: none"></span>}}
{{DISPLAYTITLE:}} NOTOC
__NOTOC__
 
<!--Hides title of Main Page-->
Neoplasm.org is an open-access knowledge base dedicated to the rapid dissemination of oncology clinical trial results and evidence-based treatment regimens. Modeled after the collaborative spirit of the medical community, our mission is to translate complex research into actionable clinical insights—free of charge and accessible to everyone, from oncologists and researchers to students and patients.
<div style="text-align:center">
 
<span class="neoplasm-title">
{| class="wikitable neoplasm-table" |- | colspan="5" class="neoplasm-quicklinks-header" | Quick links to major topic areas |- | class="neoplasm-quicklink solid" | [[#solidtumors|Solid Tumors]] | class="neoplasm-quicklink heme" | [[#malignantheme|Malignant Hematology]] | class="neoplasm-quicklink peds" | [[#peds|Pediatrics]] | class="neoplasm-quicklink transplant" | [[#transplant|Transplant & IEC]] | class="neoplasm-quicklink classical" | [[#classicalheme|Classical Hematology]] |}
'''<big>Neoplasm.org - An open Hematology/Oncology Reference</big>'''
</span>
</div>Neoplasm.org  is an open-access knowledge base dedicated to the rapid dissemination of oncology clinical trial results and evidence-based treatment regimens. Modeled after the collaborative spirit of the medical community, our mission is to translate complex research into actionable clinical insights—free of charge and accessible to everyone, from oncologists and researchers to students and patients.
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
|-
|colspan="5"; style="color:white; text-align:center; background-color:#737373"|Quick links to major topic areas
|-
|style="width: 20%; font-size:125%; background-color:#08519c"|[[#solidtumors|<span style="color:white;">Solid Tumors</span>]]
|style="width: 20%; font-size:125%; background-color:#cf0001"|[[#malignantheme|<span style="color:white;">Malignant Hematology</span>]]
|style="width: 20%; font-size:125%; background-color:#ba871a"|[[#peds|<span style="color:white;">Pediatrics</span>]]
|style="width: 20%; font-size:125%; background-color:#4a1486"|[[#transplant|<span style="color:white;">Transplant & IEC</span>]]
|style="width: 20%; font-size:125%; background-color:#31a354"|[[#classicalheme|<span style="color:white;">Classical Hematology</span>]]
|-
|}  


==Links to all main disease pages==
==Links to all main disease pages==
<span id="solidtumors"></span>
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#08519c"| '''Solid Tumors'''
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Breast Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Early breast cancer (EBC)'''
|-
|style="background-color:#eff3ff"|[[Early breast cancer|EBC, NOS]]
|style="background-color:#eff3ff"|[[Early breast cancer, HR-positive|HR-positive EBC]]
|style="background-color:#eff3ff"|[[Early breast cancer, HER2-positive|HER2-positive EBC]]
|style="background-color:#eff3ff"|[[Early breast cancer, HER2-low|HER2-low EBC]]
|-
|style="background-color:#eff3ff"|[[Early breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive EBC]]
|style="background-color:#eff3ff"|[[Early breast cancer, triple negative|Early triple-negative breast cancer (eTNBC)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Metastatic breast cancer (MBC)'''
|-
|style="background-color:#eff3ff"|[[Metastatic breast cancer|MBC, NOS]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HR-positive|HR-positive MBC]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HER2-positive|HER2-positive MBC]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HER2-low|HER2-low MBC]]
|-
|style="background-color:#eff3ff"|[[Metastatic breast cancer, HR and HER2 co-expressing|HR-positive and HER2-positive MBC]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, triple negative|Metastatic triple-negative breast cancer (mTNBC)]]
|style="background-color:#eff3ff"|[[Breast cancer, CNS metastases|CNS metastases]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Breast cancer with molecular alterations'''
|-
|style="background-color:#eff3ff"|[[Breast cancer, BRCA-mutated|BRCA-mutated Breast cancer]]
|style="background-color:#eff3ff"|[[Metastatic breast cancer, PI3K pathway-altered|PI3K pathway-altered Breast cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Dermatologic Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Melanoma'''
|-
|style="background-color:#eff3ff"|[[Melanoma|Melanoma, NOS]]
|style="background-color:#eff3ff"|[[Melanoma,_BRAF-mutated|BRAF-mutated Melanoma]]
|style="background-color:#eff3ff"|[[Melanoma,_KIT-mutated|KIT-mutated Melanoma]]
|style="background-color:#eff3ff"|[[Melanoma,_NRAS-mutated|NRAS-mutated Melanoma]]
|-
|style="background-color:#eff3ff"|[[Uveal melanoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Non-melanoma skin cancer (NMSC)'''
|-
|style="background-color:#eff3ff"|[[Cutaneous basal cell carcinoma | Cutaneous BCC]]
|style="background-color:#eff3ff"|[[Cutaneous squamous cell carcinoma | Cutaneous SCC]]
|style="background-color:#eff3ff"|[[Merkel cell carcinoma|Merkel cell carcinoma (MCC)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Endocrine Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Other endocrine cancers'''
|-
|style="background-color:#eff3ff"|[[Adrenocortical carcinoma]]
|style="background-color:#eff3ff"|[[Neuroendocrine tumor|Neuroendocrine tumor (NET)]]
|style="background-color:#eff3ff"|[[Neuroendocrine carcinoma|Neuroendocrine carcinoma (NEC)]]
|style="background-color:#eff3ff"|[[Pancreatic NET]]
|-
|style="background-color:#eff3ff"|[[Pheochromocytoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Thyroid cancer without molecular alterations'''
|-
|style="background-color:#eff3ff"|[[Thyroid cancer|Thyroid cancer, NOS]]
|style="background-color:#eff3ff"|[[Thyroid cancer, anaplastic|Anaplastic thyroid cancer (ATC)]]
|style="background-color:#eff3ff"|[[Thyroid cancer, differentiated|Differentiated thyroid cancer (DTC)]]
|style="background-color:#eff3ff"|[[Thyroid cancer, medullary|Medullary thyroid cancer (MTC)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Thyroid cancer with molecular alterations'''
|-
|style="background-color:#eff3ff"|[[Thyroid_cancer,_BRAF-mutated|BRAF-mutated Thyroid cancer]]
|style="background-color:#eff3ff"|[[Thyroid_cancer,_RET-positive|RET-positive Thyroid cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gastrointestinal Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Upper GI tract'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Esophageal cancer|Esophageal cancer, NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Esophageal adenocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Esophageal squamous cell carcinoma|Esophageal squamous cell carcinoma (ESCC)]]
|style="width: 25%; background-color:#eff3ff"|[[Gastric cancer|Gastric cancer, NOS]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Gastric cancer, HER2-positive|HER2-positive gastric cancer]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Lower GI tract'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Anal cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Appendiceal tumor]]
|style="width: 25%; background-color:#eff3ff"|[[Colon cancer|Colon cancer, NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Colon cancer, RAS wild-type|RAS wild-type colon cancer]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer|Colorectal cancer (CRC), NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, BRAF-mutated|BRAF-mutated CRC]]
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, HER2-positive|HER2-positive CRC]]
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, MSI-H or dMMR|MSI-H or dMMR CRC]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Colorectal cancer, RAS wild-type|RAS wild-type CRC]]
|style="width: 25%; background-color:#eff3ff"|[[Rectal cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Small bowel adenocarcinoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Hepatobiliary cancer'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Biliary tract cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Cholangiocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Gallbladder cancer]]
|style="width: 25%; background-color:#eff3ff"|[[Hepatocellular carcinoma|Hepatocellular carcinoma (HCC)]]
|-
|style="width: 25%; background-color:#eff3ff"|[[Periampullary adenocarcinoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Pancreatic cancer'''
|-
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer|Pancreatic adenocarcinoma, NOS]]
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer, BRCA-mutated|BRCA-mutated Pancreatic adenocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic cancer, NRG1-positive|NRG1-positive Pancreatic adenocarcinoma]]
|style="width: 25%; background-color:#eff3ff"|[[Pancreatic NET]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Genitourinary Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Kidney cancer'''
|-
|style="background-color:#eff3ff"|[[Renal cell carcinoma|Renal cell carcinoma (RCC), NOS]]
|style="background-color:#eff3ff"|[[Clear cell renal cell carcinoma|Clear cell RCC (ccRCC)]]
|style="background-color:#eff3ff"|[[Non-clear cell renal cell carcinoma|Non-clear cell RCC (nccRCC)]]
|style="background-color:#eff3ff"|[[Papillary renal cell carcinoma|Papillary RCC]]
|-
|style="background-color:#eff3ff"|[[Sarcomatoid renal cell carcinoma|Sarcomatoid RCC]]
|style="background-color:#eff3ff"|[[Renal_cell_carcinoma,_VHL-associated|VHL-associated RCC]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Male genital tract'''
|-
|style="background-color:#eff3ff"|[[Penile cancer]]
|style="background-color:#eff3ff"|[[Prostate cancer|Prostate cancer, NOS]]
|style="background-color:#eff3ff"|[[Prostate cancer, HRD-positive]]
|style="background-color:#eff3ff"|[[Testicular cancer]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Urinary tract cancer'''
|-
|style="background-color:#eff3ff"|[[Urothelial carcinoma|Urothelial carcinoma, NOS]]
|style="background-color:#eff3ff"|[[Bladder cancer]]
|style="background-color:#eff3ff"|[[Upper tract urothelial carcinoma|Upper tract urothelial carcinoma (UTUC)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Gynecologic Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Ovarian cancer'''
|-
|style="background-color:#eff3ff"|[[Ovarian cancer|High-grade serous ovarian cancer (HGSOC)]]
|style="background-color:#eff3ff"|[[Low-grade serous ovarian cancer|Low-grade serous ovarian cancer (LGSOC)]]
|style="background-color:#eff3ff"|[[Ovarian cancer, BRCA-mutated]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Other gynecologic cancer'''
|-
|style="background-color:#eff3ff"|[[Cervical cancer]]
|style="background-color:#eff3ff"|[[Endometrial cancer]]
|style="background-color:#eff3ff"|[[Gestational trophoblastic neoplasia]]
|style="background-color:#eff3ff"|[[Vulvar cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Head & Neck Oncology'''
|-
|style="background-color:#eff3ff"|[[Head and neck cancer]]
|style="background-color:#eff3ff"|[[Nasopharyngeal carcinoma|Nasopharyngeal carcinoma (NPC)]]
|style="background-color:#eff3ff"|[[Oropharyngeal_cancer,_HPV-positive|HPV+ Oropharyngeal cancer]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Mesothelioma'''
|-
|colspan="2" style="background-color:#eff3ff"|[[Malignant peritoneal mesothelioma|Malignant peritoneal mesothelioma (MPEM)]]
|colspan="2" style="background-color:#eff3ff"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Neuro-Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Primary central nervous system (CNS) malignancies'''
|-
|style="background-color:#eff3ff"|[[Anaplastic glioma]]
|style="background-color:#eff3ff"|[[Craniopharyngioma]]
|style="background-color:#eff3ff"|[[Diffuse midline glioma]] <span style="color: red"><small>New</small></span>
|style="background-color:#eff3ff"|[[Glioblastoma|Glioblastoma (GBM)]]
|-
|style="background-color:#eff3ff"|[[Low-grade glioma]]
|style="background-color:#eff3ff"|[[Meningioma]]
|style="background-color:#eff3ff"|[[Subependymal giant cell astrocytoma|Subependymal giant cell astrocytoma (SEGA)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Secondary CNS malignancies'''
|-
|style="background-color:#eff3ff"|[[CNS carcinoma]]
|style="background-color:#eff3ff"|[[CNS leukemia]]
|style="background-color:#eff3ff"|[[CNS lymphoma]]
|style="background-color:#eff3ff"|[[CNS melanoma]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Sarcoma'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Bone sarcoma'''
|-
|style="background-color:#eff3ff"|[[Bone sarcoma|Bone sarcoma, NOS]]
|style="background-color:#eff3ff"|[[Ewing sarcoma]]
|style="background-color:#eff3ff"|[[Giant-cell tumor of bone]]
|style="background-color:#eff3ff"|[[Osteosarcoma]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Soft tissue sarcoma'''
|-
|style="background-color:#eff3ff"|[[Soft tissue sarcoma|Soft tissue sarcoma (STS), NOS]]
|style="background-color:#eff3ff"|[[Alveolar soft part sarcoma|Alveolar soft part sarcoma (ASPS)]]
|style="background-color:#eff3ff"|[[Dermatofibrosarcoma protuberans]]
|style="background-color:#eff3ff"|[[Desmoid tumor]]
|-
|style="background-color:#eff3ff"|[[Epithelioid sarcoma]]
|style="background-color:#eff3ff"|[[Gastrointestinal stromal tumor|Gastrointestinal stromal tumor (GIST)]]
|style="background-color:#eff3ff"|[[Inflammatory myofibroblastic tumor|Inflammatory myofibroblastic tumor (IMT)]]
|style="background-color:#eff3ff"|[[Leiomyosarcoma|Leiomyosarcoma (LMS)]]
|-
|style="background-color:#eff3ff"|[[Liposarcoma]]
|style="background-color:#eff3ff"|[[PEComa]]
|style="background-color:#eff3ff"|[[Rhabdomyosarcoma|Rhabdomyosarcoma (RMS)]]
|style="background-color:#eff3ff"|[[Tenosynovial giant cell tumor|Tenosynovial giant cell tumor (TGCT)]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Vascular sarcoma'''
|-
|style="background-color:#eff3ff"|[[Vascular sarcoma|Vascular sarcoma, NOS]]
|style="background-color:#eff3ff"|[[Angiosarcoma]]
|style="background-color:#eff3ff"|[[Kaposi sarcoma|Kaposi sarcoma (KS)]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Thoracic Oncology'''
|-
|colspan="4" style="background-color:#bdd7e7"|'''Non-small cell lung cancer (NSCLC) without driver alterations'''
|-
|style="background-color:#eff3ff"|[[Non-small cell lung cancer |NSCLC, NOS]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, nonsquamous|Nonsquamous NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, squamous|Squamous NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, PD-L1-positive|PD-L1-positive NSCLC]]
|-
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_CNS_metastases|CNS metastases]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''NSCLC with driver alterations'''
|-
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_ALK-positive|ALK-positive NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_BRAF-mutated|BRAF-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, c-Met-positive|c-Met-positive NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_EGFR-mutated|EGFR-mutated NSCLC]]
|-
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_HER2-mutated|HER2-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_KRAS-mutated|KRAS-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, MET-mutated|MET-mutated NSCLC]]
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, NRG1-positive|NRG1-positive NSCLC]]
|-
|style="background-color:#eff3ff"|[[Non-small cell lung cancer, RET-positive|RET-positive NSCLC]]
|style="background-color:#eff3ff"|[[Non-small_cell_lung_cancer,_ROS1-positive|ROS1-positive NSCLC]]
|-
|colspan="4" style="background-color:#bdd7e7"|'''Other thoracic cancer'''
|-
|style="background-color:#eff3ff"|[[Malignant pleural mesothelioma|Malignant pleural mesothelioma (MPM)]]
|style="background-color:#eff3ff"|[[Small cell lung cancer |Small cell lung cancer (SCLC)]]
|style="background-color:#eff3ff"|[[Thymoma]]
|-
|colspan="4" style="font-size:125%; background-color:#6baed6"|'''Site-agnostic'''
|-
|style="background-color:#eff3ff"|[[BRAF]]
|style="background-color:#eff3ff"|[[EGFR]]
|style="background-color:#eff3ff"|[[ERBB2 (HER2)]]
|style="background-color:#eff3ff"|[[ERBB3 (HER3)]]
|-
|style="background-color:#eff3ff"|[[MSI-H or dMMR]]
|style="background-color:#eff3ff"|[[NTRK]]
|style="background-color:#eff3ff"|[[RET]]
|style="background-color:#eff3ff"|[[SMO or PTCH-1 (Hedgehog)]]
|-
|style="background-color:#eff3ff"|[[TMB-H]]
|style="background-color:#eff3ff"|[[Carcinoma of unknown primary|Carcinoma of unknown primary (CUP)]]
|-
|}
<span id="malignantheme"></span>


{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#cf0001"| '''Malignant Hematology'''
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Acute leukemias'''
|-
|style="width: 25%; background-color:#fee0d2"|[[Acute leukemia, KMT2A-rearranged]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, FLT3-positive | AML, FLT3-positive]]
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, IDH-mutated | AML, IDH-mutated]]
|-
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia, NPM1-mutated | AML, NPM1-mutated]]
|style="width: 25%; background-color:#fee0d2"|[[Acute promyelocytic leukemia | Acute promyelocytic leukemia (APL)]]
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia | B-cell acute lymphoblastic leukemia (B-ALL)]]
|style="background-color:#fee0d2"|[[B-cell acute lymphoblastic leukemia, Ph-positive | B-ALL, Ph+]]
|-
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (T-ALL)]]
|style="background-color:#fee0d2"|[[Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm (BPDCN)]]
|style="background-color:#fee0d2"|[[CNS leukemia]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
|-
|style="background-color:#fee0d2"|[[Chronic myeloid leukemia | Chronic myeloid leukemia (CML)]]
|style="background-color:#fee0d2"|[[Chronic myelomonocytic leukemia | Chronic myelomonocytic leukemia (CMML)]]
|style="background-color:#fee0d2"|[[Essential thrombocythemia | Essential thrombocythemia (ET)]]
|style="background-color:#fee0d2"|[[Hypereosinophilic syndrome| Hypereosinophilic syndrome (HES)]]
|-
|style="background-color:#fee0d2"|[[Myelodysplastic syndrome|Myelodysplastic syndrome (MDS)]]
|style="background-color:#fee0d2"|[[Myelofibrosis | Primary & secondary myelofibrosis (PMF/SMF)]]
|style="background-color:#fee0d2"|[[Myeloproliferative neoplasm, accelerated phase|Myeloproliferative neoplasm, accelerated phase (MPN-AP)]] <span style="color: red"><small>New</small></span>
|style="background-color:#fee0d2"|[[Polycythemia vera | Polycythemia vera (PV)]]
|-
|style="background-color:#fee0d2"|[[Systemic mastocytosis]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Aggressive lymphomas'''
|-
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
|style="background-color:#fee0d2"|[[Classical Hodgkin lymphoma|Classical Hodgkin lymphoma (cHL)]]
|style="background-color:#fee0d2"|[[CNS lymphoma]]
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma (DLBCL)]]
|-
|style="background-color:#fee0d2"|[[Diffuse large B-cell lymphoma, gastric|Gastric DLBCL]] <span style="color: red"><small>New</small></span>
|style="background-color:#fee0d2"|[[High-grade B-cell lymphoma|High-grade B-cell lymphoma (HGBL)]]
|style="background-color:#fee0d2"|[[HIV-associated lymphoma]]
|style="background-color:#fee0d2"|[[Mantle cell lymphoma|Mantle cell lymphoma (MCL)]]
|-
|style="background-color:#fee0d2"|[[Mediastinal gray-zone lymphoma|Mediastinal gray-zone lymphoma (MGZL)]]
|style="background-color:#fee0d2"|[[Primary mediastinal B-cell lymphoma|Primary mediastinal B-cell lymphoma (PMBL)]]
|style="background-color:#fee0d2"|[[Transformed lymphoma|Transformed lymphoma (TL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Indolent lymphomas'''
|-
|style="background-color:#fee0d2"|[[Chronic lymphocytic leukemia| Chronic lymphocytic leukemia (CLL/SLL)]]
|style="background-color:#fee0d2"|[[Follicular lymphoma|Follicular lymphoma (FL)]]
|style="background-color:#fee0d2"|[[Hairy cell leukemia|Hairy cell leukemia (HCL)]]
|style="background-color:#fee0d2"|[[Hodgkin lymphoma, nodular lymphocyte-predominant|Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)]]
|-
|style="background-color:#fee0d2"|[[Indolent lymphoma|Indolent lymphoma (iNHL)]]
|style="background-color:#fee0d2"|[[B-cell lymphoma of mucosa-associated lymphoid tissue|MALT lymphoma]]
|style="background-color:#fee0d2"|[[Marginal zone lymphoma|Marginal zone lymphoma (MZL)]]
|style="background-color:#fee0d2"|[[Waldenström macroglobulinemia|Waldenström macroglobulinemia (WM/LPL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Plasma cell dyscrasias'''
|-
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
|style="background-color:#fee0d2"|[[Multiple myeloma|Multiple myeloma (main page)]]
|style="background-color:#fee0d2"|[[Multiple_myeloma,_induction|MM,]] induction
|style="background-color:#fee0d2"|[[Multiple_myeloma,_consolidation_and_maintenance|MM, consolidation &]] maintenance
|-
|style="background-color:#fee0d2"|[[Multiple_myeloma,_relapsed-refractory|MM, relapsed/refractory]]
|style="background-color:#fee0d2"|[[Plasma cell leukemia|Plasma cell leukemia (PCL)]]
|style="background-color:#fee0d2"|[[POEMS syndrome]]
|style="background-color:#fee0d2"|[[Smoldering multiple myeloma|Smoldering multiple myeloma (SMM)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''T-cell and NK-cell neoplasms'''
|-
|style="background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
|style="background-color:#fee0d2"|[[Anaplastic large cell lymphoma|Anaplastic large cell lymphoma (ALCL)]]
|style="background-color:#fee0d2"|[[Cutaneous T-cell lymphoma|Cutaneous T-cell lymphoma (CTCL)]]
|style="background-color:#fee0d2"|[[Extranodal NK- and T-cell lymphoma, nasal type|Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT]]
|-
|style="background-color:#fee0d2"|[[Large granular lymphocytic leukemia|Large granular lymphocytic (LGL) leukemia]]
|style="background-color:#fee0d2"|[[NK- and T-cell lymphoma|NK- and T-cell lymphoma (NKTCL)]]
|style="background-color:#fee0d2"|[[Peripheral T-cell lymphoma|Peripheral T-cell Lymphoma (PTCL)]]
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic lymphoma (T-LBL)]]
|-
|style="background-color:#fee0d2"|[[T-cell prolymphocytic leukemia | T-cell prolymphocytic lymphoma (T-PLL)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Lymphoproliferative disorders'''
|-
|colspan="2" style="background-color:#fee0d2"|[[Castleman disease]]
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocytic disorders'''
|-
|style="background-color:#fee0d2"|[[Erdheim-Chester disease|Erdheim-Chester disease (ECD)]]
|style="background-color:#fee0d2"|[[Hemophagocytic lymphohistiocytosis|Hemophagocytic lymphohistiocytosis (HLH)]]
|style="background-color:#fee0d2"|[[Langerhans cell histiocytosis|Langerhans cell histiocytosis (LCH)]]
|style="background-color:#fee0d2"|[[Rosai-Dorfman-Destombes disease]]
|-
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Disease-agnostic'''
|-
|style="background-color:#fee0d2"|[[Malignant hematologic neoplasm, FGFR1-mutated|FGFR1]] <span style="color: red"><small>New</small></span>
|-
|}
<span id="peds"></span>


{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
{| class="wikitable neoplasm-table" |- | colspan="4" class="neoplasm-major-header solid" | '''Solid Tumors''' |- | colspan="4" class="neoplasm-subheader" | '''Soft tissue sarcoma''' |- | class="neoplasm-cell" | [[Soft tissue sarcoma|STS, NOS]] | class="neoplasm-cell" | [[Leiomyosarcoma|LMS]] | class="neoplasm-cell" | [[Liposarcoma]] | class="neoplasm-cell" | [[Rhabdomyosarcoma|RMS]] |- | class="neoplasm-cell" | [[Desmoid tumor]] | class="neoplasm-cell" | [[Epithelioid sarcoma]] | class="neoplasm-cell" | [[Gastrointestinal stromal tumor|GIST]] | class="neoplasm-cell" | [[Tenosynovial giant cell tumor|TGCT]] |}
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#ba871a"|'''Pediatric Neoplasms'''
 
|-
 
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric CNS malignancies'''
 
|-
 
|style="width: 25%; background-color:#e8d7b3"|[[Low-grade glioma, pediatric|Low-grade glioma]]
{| class="wikitable neoplasm-table" |- | colspan="4" class="neoplasm-major-header heme" | '''Malignant Hematology''' |- | colspan="4" class="neoplasm-subheader heme" | '''Acute leukemias''' |- | class="neoplasm-cell heme" | [[Acute myeloid leukemia|AML]] | class="neoplasm-cell heme" | [[Acute lymphoblastic leukemia|ALL]] | class="neoplasm-cell heme" | [[Acute promyelocytic leukemia|APL]] | class="neoplasm-cell heme" | [[CNS leukemia]] |}
|style="width: 25%; background-color:#e8d7b3"|[[High-grade glioma, pediatric|High-grade glioma]]
 
|style="width: 25%; background-color:#e8d7b3"|[[Medulloblastoma]]
 
|style="width: 25%; background-color:#e8d7b3"|
 
|-
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric hematologic neoplasms'''
|-
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric | B-cell acute lymphoblastic leukemia (B-ALL)]]
|style="background-color:#e8d7b3"|[[B-cell acute lymphoblastic leukemia, pediatric, Ph-positive | B-ALL, Ph+]]
|style="background-color:#e8d7b3"|[[T-cell acute lymphoblastic leukemia, pediatric | T-cell acute lymphoblastic leukemia (T-ALL)]]
|style="background-color:#e8d7b3"|[[Acute myeloid leukemia, pediatric | Acute myeloid leukemia (AML)]]
|-
|style="background-color:#e8d7b3"|[[Anaplastic large cell lymphoma, pediatric | Anaplastic large cell lymphoma (ALCL)]]
|style="background-color:#e8d7b3"|[[Chronic myeloid leukemia, pediatric | Chronic myeloid leukemia (CML)]]
|style="background-color:#e8d7b3"|[[Juvenile myelomonocytic leukemia | Juvenile myelomonocytic leukemia (JMML)]]
|-
|style="background-color:#e8d7b3"|[[Classical Hodgkin lymphoma, pediatric |Classical Hodgkin lymphoma (cHL)]]
|style="background-color:#e8d7b3"|[[Non-Hodgkin lymphoma, pediatric | Non-Hodgkin lymphoma (NHL)]]
|-
|colspan="4" style="font-size:125%; background-color:#d1af67"|'''Pediatric solid tumors'''
|-
|style="background-color:#e8d7b3"|[[Epithelioid sarcoma]]
|style="background-color:#e8d7b3"|[[Ewing sarcoma, pediatric|Ewing sarcoma]]
|style="background-color:#e8d7b3"|[[Hepatoblastoma]]
|style="background-color:#e8d7b3"|[[Neuroblastoma]]
|-
|style="background-color:#e8d7b3"|[[Osteosarcoma, pediatric|Osteosarcoma]]
|style="background-color:#e8d7b3"|[[Retinoblastoma]]
|style="background-color:#e8d7b3"|[[Rhabdomyosarcoma, pediatric|Rhabdomyosarcoma]]
|style="background-color:#e8d7b3"|[[Wilms tumor]]
|-
|}
<span id="transplant"></span>


{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
{| class="wikitable neoplasm-table" |- | colspan="4" class="neoplasm-major-header peds" | '''Pediatric Neoplasms''' |- | colspan="4" class="neoplasm-subheader peds" | '''Pediatric solid tumors''' |- | class="neoplasm-cell peds" | [[Neuroblastoma]] | class="neoplasm-cell peds" | [[Wilms tumor]] | class="neoplasm-cell peds" | [[Osteosarcoma, pediatric|Osteosarcoma]] | class="neoplasm-cell peds" | [[Ewing sarcoma, pediatric|Ewing sarcoma]] |}
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#4a1486"|'''Transplant and Immune Effector Cells (IECs)'''
|-
|style="width: 25%; background-color:#efedf5"|[[Stem cell mobilization]]
|style="width: 25%; background-color:#efedf5"|[[Allogeneic HSCT]]
|style="width: 25%; background-color:#efedf5"|[[Autologous HSCT]]
|style="width: 25%; background-color:#efedf5"|[[Chimeric antigen receptor T cells (CAR-T)]]
|-
|style="background-color:#efedf5"|[[Graft versus host disease|Graft versus host disease (GVHD)]]
|style="background-color:#efedf5"|[[Hepatic veno-occlusive disease|Hepatic veno-occlusive disease (VOD/SOS)]]
|-
|}
<span id="classicalheme"></span>


{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-weight: bold; width: 100%;"
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Classical Hematology'''
|-
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemostasis and thrombosis'''
|-
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]]
|style="width: 25%; background-color:#e5f5e0"|[[Acquired thrombotic thrombocytopenic purpura|Acquired thrombotic thrombocytopenic purpura (aTTP)]]
|style="width: 25%; background-color:#e5f5e0"|[[Antiphospholipid antibody syndrome|Antiphospholipid antibody syndrome (APLAS)]]
|style="width: 25%; background-color:#e5f5e0"|[[Congenital thrombotic thrombocytopenic purpura|Congenital thrombotic thrombocytopenic purpura (cTTP)]]
|-
|style="width: 25%; background-color:#e5f5e0"|[[Hemophilia A]]
|style="width: 25%; background-color:#e5f5e0"|[[Hemophilia B]]
|style="width: 25%; background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia|Heparin-induced thrombocytopenia (HIT)]]
|style="width: 25%; background-color:#e5f5e0"|[[Hereditary hemorrhagic telangiectasia|Hereditary hemorrhagic telangiectasia (HHT)]]
|-
|style="background-color:#e5f5e0"|[[Inherited thrombophilia]]
|style="background-color:#e5f5e0"|[[Thrombotic microangiopathy|Thrombotic microangiopathy (TMA)]]
|style="background-color:#e5f5e0"|[[Venous thromboembolism|Venous thromboembolism (VTE)]]
|style="background-color:#e5f5e0"|[[Von Willebrand disease|von Willebrand disease (vWD)]]
|-
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Cytopenias'''
|-
|style="background-color:#e5f5e0"|[[Aplastic anemia]]
|style="background-color:#e5f5e0"|[[Autoimmune cytopenia]]
|style="background-color:#e5f5e0"|[[Immune thrombocytopenia|Immune thrombocytopenia (ITP)]]
|style="background-color:#e5f5e0"|[[Thrombocytopenia in liver disease]]
|-
|style="background-color:#e5f5e0"|[[WHIM syndrome]]
|-
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders and Hemoglobinopathies'''
|-
|style="background-color:#e5f5e0"|[[Atypical hemolytic uremic syndrome|Atypical hemolytic uremic syndrome (aHUS)]]
|style="background-color:#e5f5e0"|[[Warm autoimmune hemolytic anemia|Warm autoimmune hemolytic anemia (WAIHA)]]
|style="background-color:#e5f5e0"|[[Cold agglutinin disease|Cold agglutinin disease (CAD)]]
|style="background-color:#e5f5e0"|[[Paroxysmal nocturnal hemoglobinuria|Paroxysmal nocturnal hemoglobinuria (PNH)]]
|-
|style="background-color:#e5f5e0"|[[Pyruvate kinase deficiency|Pyruvate kinase deficiency (PKD)]]
|style="background-color:#e5f5e0"|[[Beta thalassemia]]
|style="background-color:#e5f5e0"|[[Sickle cell disease|Sickle cell disease (SCD)]]
|-
|}


<div style="text-align:center"><big>'''[[Special:AllPages|Browse our complete index of pages]]'''</big></div>


==Additional Information==
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology & oncology professionals, and undergoes [[how to contribute|continuous peer review]].


Any information that one feels would be helpful to other oncology providers is welcome. Visit [[how to contribute]] for more details.
{| class="wikitable neoplasm-table" |- | colspan="4" class="neoplasm-major-header transplant" | '''Transplant & Immune Effector Cells''' |- | class="neoplasm-cell transplant" | [[Allogeneic HSCT]] | class="neoplasm-cell transplant" | [[Autologous HSCT]] | class="neoplasm-cell transplant" | [[CAR-T]] | class="neoplasm-cell transplant" | [[GVHD]] |}


Priorities of this project include:
<section begin=goals />
*'''Creating a database of all [[Drug index | approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology]].
*'''Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature.
*'''[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
*'''Aggregating [[External links|useful links]] to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
*'''Creating, maintaining, and disseminating a [[Ontology|formalized ontology]] of anticancer drugs and regimens.
<section end=goals />


Additional possibilities for this project may include:
*Creating synopses of pivotal clinical trials and regimens
*Prioritizing regimens by their efficacy and/or toxicity
*Capturing historical regimens that were standard-of-care prior to 2005
*Checklists for common clinical scenarios/diseases
*Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects


The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as [https://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.


<br><inputbox>
{| class="wikitable neoplasm-table" |- | colspan="4" class="neoplasm-major-header classical" | '''Classical Hematology''' |- | colspan="4" class="neoplasm-subheader classical" | '''Hemostasis and thrombosis''' |- | class="neoplasm-cell classical" | [[Venous thromboembolism|VTE]] | class="neoplasm-cell classical" | [[Hemophilia A]] | class="neoplasm-cell classical" | [[Hemophilia B]] | class="neoplasm-cell classical" | [[von Willebrand disease|vWD]] |}
type=create
width=70
placeholder=Type the name of the page you want to create
break=no
</inputbox>

Revision as of 13:34, 28 December 2025

NOTOC

Neoplasm.org is an open-access knowledge base dedicated to the rapid dissemination of oncology clinical trial results and evidence-based treatment regimens. Modeled after the collaborative spirit of the medical community, our mission is to translate complex research into actionable clinical insights—free of charge and accessible to everyone, from oncologists and researchers to students and patients.

Retrieved from "https://neoplasm.org/index.php?title=Main_Page&oldid=22"